PRP for Tendon Injuries: Tennis Elbow, Achilles, and Rotator Cuff
PWritten by: Phil KimMedically reviewed by: Dr. Robert Aki, DPMLast medically reviewed: September 8, 2026
Tendons are the tough cords that connect muscle to bone, and they heal slowly. When a tendon problem settles in, many patients ask whether platelet-rich plasma (PRP) can help. This article reviews the recent evidence for the three tendon problems patients most often bring up: tennis elbow, Achilles tendinopathy, and rotator cuff tendinopathy, and it gives an honest picture of when PRP is a reasonable conversation and when it is not.
6+ mo
where PRP's long-term edge over cortisone for tennis elbow appears
30
randomized trials in a 2025 rotator cuff PRP review
5
clinical providers on the team
How tendon injuries are different
Tendons have a limited blood supply, which is why they heal much more slowly than muscle. An injured tendon can become a long-standing problem, especially with the repetitive strain of sports, physical work, or everyday activity. On Oahu, tennis and paddle sports, running, hiking, and paddling all put repeated load on the elbows, heels, and shoulders.
Tennis elbow (lateral epicondylitis)
Tennis elbow is irritation of the tendons on the outside of the elbow, usually from overuse. The evidence for PRP here is among the most encouraging in the regenerative field. A 2025 meta-analysis of randomized trials found that while corticosteroid injections gave faster short-term relief, PRP produced significantly better pain relief and function over the long term, beyond six months. For people whose elbow pain has persisted for months, that durability is often exactly what matters.
“Corticosteroids provided faster short-term relief, but PRP produced significantly better long-term pain relief and functional scores for lateral epicondylitis, with the advantage emerging beyond six months.”
Achilles tendinopathy
The evidence for the Achilles tendon is more mixed. Some reviews report significant pain reduction and functional improvement, while others, including a 2025 meta-analysis in Clinical Orthopaedics and Related Research, found no clear advantage over control treatments. In practice, PRP may help some people with Achilles problems, but it is not a guaranteed answer, and a structured rehabilitation program is usually the foundation of care.
Rotator cuff tendinopathy
For the shoulder, a 2025 systematic review of roughly 30 randomized trials found that PRP can provide meaningful short-term pain relief, but evidence for a long-term advantage over other treatments is limited. Regenerative options can still play a supporting role in a shoulder recovery plan, which is exactly why a thorough evaluation should come before any decision.
Who might reasonably consider PRP
Chronic tendon pain that has persisted despite structured rehabilitation
A diagnosis confirmed by physical examination and, commonly, imaging such as ultrasound or MRI
No partial or full tear or other structural problem that needs different care
Realistic expectations that PRP supports healing over weeks and months, rather than working overnight
What a PRP tendon visit here involves
At Aloha Stem Cell, a tendon consultation starts with a conversation and a focused physical exam, with imaging reviewed if you have it. Treatment draws a small amount of your own blood, concentrates the platelets in a centrifuge, and injects them into the affected area under local numbing, typically in a single outpatient visit. You leave with a recovery plan, follow-up guidance, and a number to call with questions.
A note from the clinic
Tendon problems deserve an accurate diagnosis before any injection, because a partial or full tear is treated very differently from a strain. Call (808) 593-2525 to talk through your elbow, heel, or shoulder with our team in Honolulu.
Our team is happy to listen to your story, answer your questions, and help you decide
whether a consultation makes sense. There is no pressure and no obligation.
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.